Valuation: ProPhase Labs, Inc.

Market Cap 140K 125K 115K 104K 195K 13.25M 198K 1.37M 550K 6.97M 524K 512K 21.98M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 8.67M 7.76M 7.14M 6.47M 12.09M 823M 12.32M 85.15M 34.18M 433M 32.53M 31.84M 1.37B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
87.51%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-3.75%
1 week-16.30%
Current month-36.26%
1 month-36.26%
3 months-84.60%
6 months-94.11%
Current year-98.28%
1 week 0.01
Extreme 0.0075
0.01
1 month 0.01
Extreme 0.0075
0.02
Current year 0.01
Extreme 0.0075
0.47
1 year 0.01
Extreme 0.0075
3.65
3 years 0.01
Extreme 0.0075
74.8
5 years 0.01
Extreme 0.0075
152.5
10 years 0.01
Extreme 0.0075
160.4
Manager TitleAgeSince
Chief Executive Officer 67 18/06/2009
Director of Finance/CFO 66 05/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Director/Board Member 70 31/05/2009
Chairman 67 18/06/2009
Director/Board Member 56 19/06/2025
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/25 Free

Chief Executive Officer

500,000 1.2036%
17/02/25 Free

Chief Operating Officer

500,000 1.6737%
14/02/25 Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-3.75%-16.30%-99.79%-99.98% 140K
-0.09%-3.44%+17.68%+32.70% 115B
-1.02%+0.89%+1.37%+111.87% 98.85B
-4.98%+2.56%+114.42%+1,003.33% 59.72B
-1.84%+9.86%+43.22%+82.37% 29.34B
+1.44%+1.95%-6.67%+93.57% 30.06B
-0.43%+4.11%+43.28%+94.59% 27.71B
+0.99%+1.79%+30.98%+413.15% 22B
-0.72%+5.53%-18.63%-12.38% 20.66B
0.00%-0.63%-4.27%+31.71% 17.09B
Average -1.04%+0.63%+12.16%+175.09% 42.09B
Weighted average by Cap. -1.01%+1.07%+27.33%+218.55%

Financials

2024 2025
Net sales 6.77M 6.06M 5.58M 5.05M 9.45M 643M 9.62M 66.51M 26.7M 338M 25.41M 24.87M 1.07B 4.34M 3.89M 3.58M 3.24M 6.06M 413M 6.18M 42.69M 17.14M 217M 16.31M 15.96M 684M
Net income -53.36M -47.79M -43.96M -39.83M -74.46M -5.07B -75.85M -524M -210M -2.67B -200M -196M -8.41B -14.74M -13.2M -12.15M -11M -20.57M -1.4B -20.96M -145M -58.14M -736M -55.33M -54.15M -2.32B
Net Debt 23.9M 21.4M 19.68M 17.84M 33.34M 2.27B 33.96M 235M 94.23M 1.19B 89.68M 87.77M 3.76B 8.53M 7.64M 7.03M 6.37M 11.9M 810M 12.12M 83.78M 33.63M 426M 32M 31.32M 1.34B
Projected Income Statement - Annual - ProPhase Labs, Inc.
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
30/10/26 US$0.007700 -3.75% 145,811
29/10/26 US$0.008000 -11.11% 22,218
28/10/26 US$0.009000 +4.65% 1,142,833
27/10/26 US$0.008600 -4.44% 3,714
26/10/26 US$0.009000 -2.17% 76,290

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ProPhase Labs, Inc.
  1. Stock Market
  2. Stocks
  3. PRPH Stock